Advances in tumor markers

BAI Rilan; LIANG Tingting; CUI Jiuwei

doi:10.3981/j.issn.1000-7857.2021.07.003

PDF(632 KB)

Science & Technology Review ›› 2021, Vol. 39 ›› Issue (7) : 28-37. DOI: 10.3981/j.issn.1000-7857.2021.07.003

Exclusive: Tumor Markers

Advances in tumor markers

Author information -

Cancer Center, The First Hospital of Jilin University, Changchun 130021, China

Abstract

With the development of precision medicine, tumor markers have been paid more and more attention by researchers, and their understanding has gradually made a breakthrough. The research content of tumor markers has been gradually expanded to tumor markers based on tumor genome and chromosomal variations, liquid biopsy, epigenetics and metabolomics; moreover, tumor marker-related detection technologies have developed rapidly, including liquid biopsy, high-throughput gene sequencing, single-cell sequencing and other new technologies; furthermore, with the continuous development of these new high-technologies, tumor marker detection has achieved a breakthrough from single detection to multi-factor combined detection; finally, in clinical practice, tumor marker detection has played an important role in early tumor screening and diagnosis, guiding tumor treatment and predicting efficacy as well as predicting tumor recurrence, metastasis and prognosis, which is of great significance to improve the quality of cancer diagnosis and treatment, and fully realize precision medicine.

Key words

neoplasm / tumor markers / liquid biopsy / high-throughput sequencing / clinical application

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

BAI Rilan, LIANG Tingting, CUI Jiuwei. Advances in tumor markers[J]. Science & Technology Review, 2021, 39(7): 28-37 https://doi.org/10.3981/j.issn.1000-7857.2021.07.003

References

[1] Rubis G D, Krishnan S R, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis[J]. Trends in Pharmacological Sciences, 2019, 40(3):172-186.
[2] Mader S, Pantel K. Liquid biopsy:Current status and future perspectives[J]. Oncology Research and Treatment, 2017, 40(7-8):404-408.
[3] Cabel L, Proudhon C, Romano E, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy[J]. Nature Reviews Clinical Oncology, 2018, 15(10):639-650.
[4] Rubis G D, Krishnan S R, Bebawy M. Circulating tumor DNA-current state of play and future perspectives[J]. Pharmacological Research, 2018, 136:35-44.
[5] Paolillo C, Londin E, Fortina P. Next generation sequencing in cancer:Opportunities and challenges for precision cancer medicine[J]. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 245:84-91.
[6] Arboleda V A, Xian R R. An overview of DNA analytical methods[J]. Methods in Molecular Biology, 2019, 1897:385-402.
[7] Duffy M J, O'Byrne K. Tissue and blood biomarkers in lung cancer:A review[J]. Advances in Clinical Chemistry, 2018, 86:1-21.
[8] Li W, Zhang M, Huang C, et al. Genetic variants of DNA repair pathway genes on lung cancer risk[J]. Pathology Research and Practice, 2019, 215(10):152548.
[9] 白日兰, 刘一凝, 崔久嵬. 肺癌的遗传咨询与精准诊疗策略[J]. 中国肿瘤生物治疗杂志, 2020, 27(8):835-842.
[10] Ji Z, Li Y, Xiang C, et al. TERT-rs33963617 and CLPTM1L-rs77518573 reduce the risk of non-small cell lung cancer in Chinese population[J]. Gene, 2020, 731:144357.
[11] Li Y, Xiang C, Shen N, et al. Functional polymorphisms on chromosome 5p15.33 disturb telomere biology and confer the risk of non-small cell lung cancer in Chinese population[J]. Molecular Carcinogenesis, 2019, 58(6):913-921.
[12] 景丽, 郑杰. 染色体易位与恶性肿瘤[J]. 中华病理学杂志, 2011(2):138-140.
[13] 李洁. 食管鳞癌中1号染色体长臂杂合性缺失的研究[D]. 北京:北京协和医学院, 2004.
[14] 王晓玫, 彭全洲, 单军, 等. 3p杂合性缺失与非小细胞肺癌的相关性[J]. 广东医学, 2007, 28(7):1060-1062.
[15] Postel M, Roosen A, Laurent-Puig P, et al. Dropletbased digital PCR and next generation sequencing for monitoring circulating tumor DNA:A cancer diagnostic perspective[J]. Expert Review of Molecular Diagnostics, 2018, 18(1):7-17.
[16] Guo S, Diep D, Plongthongkum N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nature Genetics, 2017, 49(4):635-642.
[17] Andree K C, van Dalum G, Terstappen L W. Challenges in circulating tumor cell detection by the CellSearch system[J]. Molecular Oncology, 2016, 10(3):395-407.
[18] Gkountela S, Castro-Giner F, Szczerba B M, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding[J]. Cell, 2019, 176(1-2):98-112.e114.
[19] Shao H, Im H. New technologies for analysis of extracellular vesicles[J]. Chemical Reviews, 2018, 118(4):1917-1950.
[20] Gholizadeh S, Shehata D M, Zarghooni M, et al. Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles:Current status and future directions[J]. Biosensors & Bioelectronics, 2017, 91:588-605.
[21] Chen G, Huang A C, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718):382-386.
[22] Melo S A, Luecke L B, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J]. Nature, 2015, 523(7559):177-182.
[23] Brabender J, Usadel H, Danenberg K D, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival[J]. Oncogene, 2001, 20(27):3528-3532.
[24] Li J, Li Y, Li W, et al. Guide positioning sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks[J]. Genome Research, 2019, 29(2):270-280.
[25] Feng Q, Hawes S E, Stern J E, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients[J]. Cancer Epidemiol Biomarkers Prevention, 2008, 17(3):645-654.
[26] Lomberk G, Mathison A J, Grzenda A, et al. The sunset of somatic genetics and the dawn of epigenetics:A new frontier in pancreatic cancer research[J]. Current Opinion in Gastroenterology, 2008, 24(5):597-602.
[27] Schneider G, Krämer O H, Schmid R M, et al. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma[J]. Journal of Gastrointestinal Cancer, 2011, 42(2):85-92.
[28] Li M, Li A, He R, et al. Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility[J]. Cancer Medicine, 2019, 8(10):4892-4905.
[29] Haiges D, Kurz P, Laaff H, et al. Malignant PEComa[J]. Journal of Cutaneous Pathology, 2018, 45(1):84-89.
[30] Abbott J, Teleni L, McKavanagh D, et al. Patient-generated subjective global assessment short form (PG-SGA SF) is a valid screening tool in chemotherapy outpatients[J]. Supportive Care in Cancer, 2016, 24(9):3883-3887.
[31] Yagi T, Shoaib M, Kuschner C, et al. Challenges and inconsistencies in using lysophosphatidic acid as a biomarker for ovarian cancer[J]. Cancers (Basel), 2019, 11(4):520.
[32] Ferro M, Buonerba C, Terracciano D, et al. Biomarkers in localized prostate cancer[J]. Future Oncology, 2016, 12(3):399-411.
[33] Nishiumi S, Kobayashi T, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer[J]. PLoS One, 2012, 7(7):e40459.
[34] Szczerba B M, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745):553-557.
[35] Routy B, Le Chatelier E. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97.
[36] Xu H, Baidoo A A H, Su S, et al. A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients[J]. Translational Lung Cancer Research, 2019, 8(2):135-143.
[37] Li X, Ren R, Ren S, et al. Peripheral blood for epidermal growth factor receptor mutation detection in nonsmall cell lung cancer patients[J]. Translational Oncology, 2014, 7(3):341-348.
[38] Hung M S, Lung J H, Lin Y C, et al. Comparative analysis of two methods for the detection of egfr mutations in plasma circulating tumor DNA from lung adenocarcinoma Patients[J]. Cancers (Basel), 2019, 11(6):803.
[39] Buermans H P, den Dunnen J T. Next generation sequencing technology:Advances and applications[J]. Biochimica et Biophysica Acta, 2014, 1842(10):1932-1941.
[40] Li Y, Xu H, Su S, et al. Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma[J]. PLoS One, 2017, 12(8):e0183331.
[41] Li Z, Wang Z, Tang Y, et al. Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics[J]. Nature Communications, 2019, 10(1):3856.
[42] Goldstein L D, Cao Y, Pau G, et al. Prediction and quantification of splice events from RNA-Seq data[J]. PLoS One, 2016, 11(5):e0156132.
[43] Steijger T, Abril J F, Engstrom P G, et al. Assessment of transcript reconstruction methods for RNA-seq[J]. Nature Methods, 2013, 10(12):1177-1184.
[44] Wiedmeier J E, Noel P, Lin W, et al. Single-cell sequencing in precision medicine[J]. Cancer Treatment and Research, 2019, 178:237-252.
[45] Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma[J]. Cell, 2019, 179(4):829-845.
[46] Rodriques S G, Stickels R R. Slide-seq:A scalable technology for measuring genome-wide expression at high spatial resolution[J]. Science, 2019, 363(6434):1463-1467.
[47] Dagher M, Kleinman M, Ng A, et al. Ensemble multicolour FRET model enables barcoding at extreme FRET levels[J]. Nature Nanotechnology, 2018, 13(10):925-932.
[48] Campanella G, Hanna M G, Geneslaw L, et al. Clinicalgrade computational pathology using weakly supervised deep learning on whole slide images[J]. Nature Medicine, 2019, 25(8):1301-1309.
[49] Abelson S, Collord G, Ng S W K, et al. Prediction of acute myeloid leukaemia risk in healthy individuals[J]. Nature, 2018, 559(7714):400-404.
[50] Krug A K, Enderle D, Karlovich C, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma[J]. Annals of Oncology, 2018, 29(3):700-706.
[51] Reck M, Mok T S K, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150):Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respiratory Medicine, 2019, 7(5):387-401.
[52] Ascierto M L, Kmieciak M, Idowu M O, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients[J]. Breast Cancer Research and Treatment, 2012, 131(3):871-880.
[53] Ribas A, Robert C, Hodi F S, et al. Association of response to programmed death receptor 1(PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature[J]. Polymer International, 2015, 33(2):141-147.
[54] Zhang C, Yu W, Wang L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. Journal of Cancer, 2017, 8(17):3585-3591.
[55] Cohen J D, Li L. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378):926-930.
[56] Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT):A phase 2, single-arm, multicentre clinical trial[J]. Lancet Respiratory Medicine, 2018, 6(9):681-690.
[57] Lee J H, Long G V, Menzies A M, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies[J]. JAMA Oncology, 2018, 4(5):717-721.
[58] Wang Y, Li L, Cohen J D, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J]. JAMA Oncology, 2019, 5(8):1118-1123.
[59] Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J]. JAMA Oncology, 2019, 5(3):376-383.